Sandoz pulls injectable methotrexate due to particulate matter

05/22/2013 | MedPage Today (free registration)

Sandoz recalled two lots of its methotrexate sodium USP, 25 mg/mL, 40 mL vial injectable drug, which is indicated for rheumatoid arthritis, severe psoriasis and neoplastic diseases. The drugmaker found particulate matter in vials of lots CL0996 and CJ4948 while performing a routine quality inspection. Parenteral injection of the recalled products "can lead to microembolisation in areas where the particles lodge," the FDA warned in its recall notice.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ